From DCAT Value Chain Insights (VCI)
Vertex Pharmaceuticals Incorporated has appointed David Altshuler, MD, Ph.D., as executive vice president, global research and chief scientific officer. Dr. Altshuler was one of the four founding members of the Broad Institute of Harvard University and the Massachusetts Institute of Technology, where he has served as deputy director and chief academic officer since 2009.
Dr. Altshuler is also currently a professor of genetics and medicine at Harvard Medical School and an adjunct professor of biology at the Massachusetts Institute of Technology and has been an attending physician at the Massachusetts General Hospital. His scientific research has been focused on the discovery of new pathophysiological processes underlying the risk of developing Type 2 diabetes to identify and validate new drug targets. At Vertex, Dr. Altshuler will lead the company's research efforts aimed at discovering new medicines for the treatment of serious diseases, overseeing activities across the company's five research sites in the United States, Canada, and Europe.
Dr. Altshuler has resigned from his position as a Vertex director and will begin his new role at Vertex in early 2015.
Source: Vertex Pharmaceuticals
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription